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Abstract
A broad spectrum of conditions classically requires a colposcopic assessment for either 
diagnostic or treatment means, including atypical changes in the cervix-vagina and 
vulva, abnormal Pap tests, cervicitis, polyps, cervical warts, genital warts, and bleed-
ing. Although the procedure is commonly considered as criteria for the management of 
cervical cancer, the sensitivity of colposcopy is quite limited as its ability to discriminate 
among dysplasia and microinvasive carcinoma is difficult. Most professional societies 
and international health organizations have already released guidelines and recommen-
dation for the management for woman with abnormal cervical pathology (e.g., cervical 
intraepithelial neoplasia and cervical cancer); only women with positive human papil-
lomavirus (HPV) tests, low-grade squamous intraepithelial lesion (LSIL), or severe cytol-
ogy have clear indication for referral to a colposcopic evaluation. While most guidelines 
recommend colposcopy for any abnormal cytology or any positive HPV test, others 
apply only for woman with two consecutive unsatisfactory Pap tests or for those with 
some abnormalities. In conclusion, cervical cancer risk remains high; thus, the potential 
benefit of colposcopy examination should be balanced against the risk.
Keywords: colposcopy, Pap test, cervical cancer, low-grade squamous intraepithelial 
lesion, high-grade squamous intraepithelial lesion
1. Introduction
When we have abnormal changes at the cervix-vagina and vulva, colposcopy may be used and 
the normal view is enlarged by the eye alone. Sometimes, PAP tests show abnormal changes 
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in the cervix cells, thus colposcopy may be recommended to be done. Also, the procedure is 
performed to assess the results of a treatment or other disturbances: cervicitis, polyps, cervical 
warts, genital warts, and bleeding.
However, these techniques might have been expected to contribute toward managing women 
with abnormal cytology.
Also, the sensitivity of colposcopy is limited: the ability of colposcopy to discriminate among 
dysplasia and microinvasive carcinoma can be difficult. Cervical cancer prevention is a pro-
cess using a combination between and biopsy, cytology, and human papillomavirus (HPV)-
DNA testing.
The colposcopic appearances of vaginal squamous cancer may require biopsy for diagnosis 
because primary squamous cancer of the vagina is extremely rare. Colposcopists usually eval-
uate visual characteristics of the dysplastic lesions and cervical cancer. Once the diagnosis of 
the invasive cervical cancer has been established, delay in the treatment may carry a great risk 
of tumor progression. The procedure of colposcopy is used in the criteria for the management 
of cervical cancer and as a part of continuous professional self-development.
Most professional societies and international health organizations had created similar guide-
lines management for woman with abnormal cervical pathology including cervical intraepi-
thelial neoplasia (CIN) or cervical cancer.
Women were referred to colposcopy only if they had positive HPV tests, low-grade squamous 
intraepithelial lesion (LSIL), or severe cytology.
Current guidelines recommend colposcopy for any abnormal cytology or any positive HPV 
test. Other guidelines apply only for woman with two consecutive unsatisfactory PAP tests or 
for those with some abnormalities.
In conclusion, cervical cancer risk remains high; thus, the potential benefit of colposcopy 
examination should be balanced against the risk.
2. Definition and why it is performed
Colposcopy is a procedure that allows physicians to examine the cervix, vagina, and vulva 
using a device called colposcope, which looks like a pair of binoculars mounted on a stand. 
When we have abnormal changes at the cervix-vagina and vulva, colposcopy may be used 
and the normal view is enlarged by the eye alone. The colposcope is used to determine the 
presence of abnormal areas. When the result of a smear is abnormal, the person performing 
the colposcopy (colposcopist) will be able to see problem areas more clearly. These changes 
are graded as mild, moderate, or severe and some are reported as “borderline”. There is an 
adequate treatment for such changes depending on the nature of the condition. They could 
become cancerous if they were left untreated. Also, the procedure is performed to assess the 
results of a treatment or other disturbances: cervicitis, polyps, cervical warts, genital warts, 
bleeding, etc. However, these techniques might have been expected to contribute toward 
managing women with abnormal cytology [1, 2].
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It is now accepted that women who have abnormal Pap smear reports, CIN I, human papil-
lomavirus, atypia, CIN II, CIN III, or even inflammation should be referred for colposcopy. 
There are many uncertainties and confusion about the significance of preclinical cervical car-
cinoma or changes in the cervix at a precancerous stage [1].
Also, abnormalities could become cancerous but this may take a number of years, and if they 
do it will cause alarm in women.
Inadequate smear results, postcoital bleeding, intermenstrual bleeding, and/or concerning 
appearance of the cervix are regarded as being reasons for women having referred for col-
poscopic examination. Also, it is useful for the evaluation of various vaginal or vulvar lesions [1].
3. What does the procedure involve
The colposcopic examination involves the visualization of the vascular pattern and epithelial 
opacity. The procedure means to look into the vagina and does not touch or go inside the 
body. Colposcopy can be expected to identify the area of the cervix called transformation 
zone. In addition, it is necessary to learn how the colposcopic examination can be made based 
on the natural history of cervical intraepithelial neoplasia understanding [1].
The colposcopist may wish to examine the cervix, vagina, or vulva and take a biopsy. This 
may need the injection of local anesthetic. Then, the biopsy is sent to the pathologist who will 
confirm the diagnosis of cervical intraepithelial neoplasia or cervical carcinoma. However, 
these precancerous changes will never progress further or can take many years in order to be 
reassured of having cervical cancer [1, 3].
It is possible for pregnant women to develop cervical cancer if they have previously had an 
abnormal Pap smear in the last 3–5 years. A colposcopy is a simple procedure that can be 
done safely during pregnancy; thus, colposcopy can be arranged. If the colposcopist observes 
any changes on the cervix surface, it is safe to take biopsies. The examination will usually 
be repeated until 6 months to check on the progress of the changes of the cervix. Because 
pregnancy can make the result of Pap smear difficult to interpret, cervical cancer screening 
is unnecessary during this period. Then, the procedure can be repeated during or/and 1–3 
months after delivery in order to confirm the presence of precancerous conditions or to con-
firm the presence of cervical cancer [1, 4, 5].
4. Precancerous changes confirmed after colposcopy
Cervical intraepithelial neoplasia is graded as mild (CIN I), moderate (CIN II), or severe (CIN 
III).
Over the past decades, gynecologists and other health-care experts representing national 
and international health organizations identified strategies for the management of women 
with abnormal Pap smear and cervical intraepithelial neoplasia (CIN). These guidelines have 
greatly affected the optimal approach to hysterectomy in women with risks for cancer [2, 6, 7].
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Cervical cancer risk is attributed to human papillomavirus (HPV) infection.
In agreement with other reports, an effective screening for preinvasive squamous lesions may 
be associated with adequate diagnostic measures, including colposcopic examination.
We can stop the growth of cancer development by using colposcopy to confirm whether it is 
cervical intraepithelial neoplasia or cancer [1, 2, 3, 8].
The abnormalities in the surface of the cervix are known as CIN. CIN indicates changes in the 
squamous cells of the surface layer of the cervix and rarely caused any symptoms.
Almost all Obstetrics and Gynecology Clinical Hospitals in Romania have the facilities for 
undergoing colposcopy.
The colposcopists may plan the treatment for most of the women who have abnormal areas at 
the surface of the cervix depending on the grade of CIN.
The cell changes that go deep into the cervix affecting one-third of the thickness of cervix 
indicates CIN I or mild changes. In order to find the grade of CIN, when two-thirds of the 
thickness of cervix is affected by abnormal cells it indicates CIN II or moderate to marked 
changes, and when the full thickness of cervix is affected it indicates CIN III or severe dyspla-
sia to carcinoma in situ [1, 8–10].
Usually, most women who have an abnormal result at the screening test do not have cancer.
The Pap smear abnormalities are called squamous intraepithelial lesions (SILs). According to 
the National Guidelines, these changes are low-grade (LSIL), high-grade (HSIL), malignant 
atypical glandular cells of undetermined significance (AGUS), or atypical squamous cells 
(ASCUS) [1].
The high-risk types of HPV may be identified by HPV-DNA test. It can be done at any age 
for women who have an abnormal Pap test. The treatment depends on the degree of CIN and 
may include cryosurgery, laser therapy, loop electrosurgical excision procedure (LEEP), cone 
biopsy, or hysterectomy [3, 11, 12].
In most cases, the specialist may take a biopsy that may cause bleeding, discharge or pain, and 
cervical intraepithelial neoplasia. There are two different cervical cells in the cervix: glandular 
cells (endocervix) and squamous cells (ectocervix).
The aim of organized screening program is to reduce cervical cancer mortality by detecting 
changes in the cervix when they are still in precancerous stage and can be treated.
The percentage of cancers diagnosed during the program is an important factor, and leads to 
an increased willingness to participate in the screening program. However, some participants 
chose not to receive specific treatment regardless of a wide range of reasons. This suggests 
that the association between research and screening programs is the key issues for accurate 
measures of the benefits of cervical cancer screening [1, 3, 12, 13].
In distinguishing who will and who will not develop cervical cancer, it is the current clinical 
guidelines that matter.
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5. Colposcopy as a diagnostic, screening tool, and gathering information
Cervical cancer remains one of the most common gynecological malignancies in developing 
countries.
The use of colposcopy is an effective screening tool for cervical cancer due to its high nega-
tive-predictive value. Some of the justifications against its utilization are the probability of 
producing unnecessary distress, bleeding more than you experience during your period if a 
biopsy is performed, chills, fever or severe pelvic pain, allergy to iodine and latex, infection, 
and false-negative results (the chance that women would develop CIN II or CIN III is low). 
Furthermore, there is a range of accepted thresholds including acute inflammation of cervix, 
acute pelvic inflammatory disease, and having your period.
Before colposcopic examination is performed, women must be fully informed about the pos-
sibility of the risks and other important information including no vaginal medication or tam-
pon use, and no tub bathing or sex after the examination [1, 5].
Numerous symptoms that may concern you have been identified and include red bleeding, 
smelling discharge, fever, pelvic pain, chills, or spotting.
The colposcopist may confirm the presence of abnormal areas in the transformation zone as 
lesion size, lesion margin, acetowhite zone, and blood vessel pattern in order to select biopsy 
sites of the cervix [1, 11].
Among the limitations of colposcopy, we found that colposcopic sensitivity is known to cor-
relate with the lesion size.
Recent data revealed that lesion size was associated with the degree of CIN and HPV geno-
type. Thus, smaller lesions are known to cause more false-negative cervical smears than larger 
lesions [1, 2, 6, 8].
Among several signs, the relationship between colposcopic characteristics and grades of CIN 
may make colposcopic assessment to have more benefits in the identification of preclinical 
lesions whose capacity for progression to cervical cancer has been demonstrated [1, 14, 15].
The European Federation for Colposcopy has developed a program of instruction for special-
ists and residents that should lead to a reduced number of cervical cancer cases.
We believe that the management of cervical abnormalities by cytology, colposcopy, and his-
tological direct biopsy appraisal can help us to distinguish between low-grade lesions and 
malignancy that may affect the lower genital tract [1, 5, 16].
Both physicians and pathologists need to be aware of the existence of such cervical lesions to 
avoid unnecessary invasive treatments.
Developing countries have a high incidence rate compared to developed countries, so unde-
tected pre-malignant lesions can lead to invasive cervical cancer [1, 15].
The colposcopic evaluation and careful examination of pathologic specimens showed that 
almost 100% of women with CIN contain HPV [1, 13, 17, 18].
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It is now accepted that women with cervical abnormalities should be referred for colposcopy.
Clinical guidelines for health-care professionals are available for government organizations, 
professional societies, and researchers. These guidelines are designed to provide efficient 
monitoring and should help health-care professionals specifying actions to be taken to avoid 
or minimize the risk of cervical cancer. Most professional societies and international health 
organizations had created similar guidelines management for woman with abnormal cervical 
pathology including cervical intraepithelial neoplasia (CIN) or cervical cancer [1, 5, 12, 19].
It is possible that the number of women who have had a Pap smear in the previous 5 years is 
to be overestimated because patients who have had a hysterectomy were not excluded and 
reduce the frequency of colposcopic examination [1, 5, 11, 15].
In the case of screening program, guidelines will decrease the high frequency of the cervical 
cancer. Also, they showed us an improvement in the detection of intraepithelial lesions.
The ingenious conventional Pap smear or cervical cytology remained unchanged for over six 
decades. Most notable is that Bethesda terminology for cytology results had created the opti-
mal screening guidelines in managing women with abnormal Pap smear results.
The Bethesda system has set the terminology and management for human papillomavirus-
associated ano-genital lesions. The terminology should be relevant, uniform, and reproducible 
across laboratories in a wide variety of countries. This includes negative, atypical squamous 
cells of undetermined significance (ASC-US), atypical squamous cells that cannot exclude HSIL 
(ASC-H), low-grade intraepithelial lesions (LSIL), high-grade squamous intraepithelial lesions 
(HSIL), atypical glandular cells of undetermined significance (AGUS), and positive [1, 11, 20–22].
For women with LSIL, if the HPV test is positive or repeat cytology at 12 months is ASC-US, 
colposcopy is recommended.
For women with HSIL, if colposcopy is inadequate a diagnostic biopsy procedure is preferred.
For women with atypical glandular cells (AGC) and adenocarcinoma in situ (AIS), colposcopy 
is recommended in conjunction with endocervical and endometrial sampling [1, 11, 12, 23].
The Consensus Guidelines were updated by the American Society of Cytopathology. These 
are the result of a great effort to provide the current management algorithms for the world 
clinician’s community [1, 13, 24].
The Bethesda system was the first to use the cervical cytology with patient history, clinical 
findings, and cervical biopsy to provide the best course of patient management and to reduce 
confusion among laboratories.
Most of the recent studies use the liquid-based technology in the detection of cervical cancer 
precursors. There are few clinical trials reporting a significant improvement in the detection 
of ASC-US, AGC-US, or adenocarcinoma [5, 11, 25].
According to the Cervical Cancer Screening Guidelines, the unsatisfactory cytology should 
be repeated, suggesting that colposcopic examination is necessary for those women with two 
consecutive unsatisfactory cytologies [1, 5, 11, 25].
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More than 200 types of Human Papillomavirus (HPVs) have been identified based on their 
DNA sequence. In the case of cervical infection, HPV is transmitted by sexual contact. Also, 
HPV can be spread by anal or oral sex. Most of the high-risk HPV infections do not cause can-
cer but some of them may persist for many years leading to abnormalities that, if untreated, 
may develop cancer [1, 13, 17, 21].
According to the HPV type found in cervical carcinoma, the high-risk types, such as HPV 16 
and HPV 18, are associated with HPV-caused cancers [1, 5, 11].
Some specialists are using anal Pap tests for men who are at a greater risk of anal cancer 
caused by high-risk HPV types. Several vaccines are currently approved by the Food and 
Drug Administration (FDA). Since 2006, Gardasil was approved for use in females. In the later 
years, the same vaccine was approved for men [11, 15, 26–28].
Is the risk of developing cancer following HPV infection in anal, penile, or oropharyngeal 
tissues many times higher than that following HPV infection in cervix? An appreciation of 
the HPV-mediated carcinogenesis of the high-risk HPV types and low-risk HPV types is still 
under investigation [1, 26, 28].
It is important to note that the majority of women with HPV infection of the genitalia including 
genital warts, precancerous changes of the cervix, and cancers can be treated.
HPV is a double-stranded circular DNA virus consisting of three regions: early gene region 
involved in viral replication and oncogenesis, late region which encodes the L1 and L2 pro-
teins for the viral capsid, and upstream regulatory region (URR) which contains the greatest 
degree of variation in the viral genome.
HPV integration is associated with the highest degree of variation in the virus genome and 
with overexpression of the E6 and E7 oncoproteins. Instability of the host cell genome is the 
first step in the progression to cervical cancer [1, 28–30].
Several reports have indicated that the immune response plays a critical role in the progression 
from HPV infection to cancer.
The sensitivity and specificity of screening with speculoscopy combined with cytology were 
superior for large lesions compared to small lesions. Colposcopy is a diagnostic tool requiring 
time, costs, and special training; therefore, speculoscopy may be added for large or very large 
lesions in order to visualize the vagina and cervix [1, 5].
The colposcopic examination remained the recommended approach for identifying all abnor-
mal lesions except for atypical squamous cells of undetermined significance(ASC-US).
Specific equipment for the colposcopic examination, the modern colposcope, is equipped 
with a built-in light source, binocular lenses, optical tubes, and the capability of course focus-
ing and variable magnification through low, medium and high levels. Colposcopes may be 
equipped with variable magnification levels or single magnification so that colposcopists can 
have the best details. They have to take responsibility and avoid misguided interpretation of 
the reports [1].
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The colposcopist and the pathologist should agree with the classification that will be given for 
cytologic or histologic interpretation.
The colposcopes are outfitted with an incandescent, xenon, tungsten, or halogen light, 
although colposcopy is sensitive for identifying the vascular pattern of the epithelium by 
using the green filter [1].
Recent technologies allow the examiner to identify the most severe lesions by a grading sys-
tem that includes color, margin, and vessels. Also, the sensitivity of colposcopy is limited: the 
ability of colposcopy to discriminate among dysplasia and microinvasive carcinoma can be 
difficult. Cervical cancer prevention is a process using a combination between biopsy, cytol-
ogy, and HPV-DNA testing [1, 9, 17, 25].
In a manner similar to laparoscopic procedure, video colposcopy will provide electronic trans-
mission of data including demographic information and actual findings of lesions. However, 
colposcopists using video colposcopy should record the colposcopic findings including ace-
towhite epithelium, leukoplakia, mosaic, punctuation, and atypical vessels on the cervix, 
vulva, or vagina. The high-quality images can be scanned into a digital format for monitoring 
regression or progression of the lesions. All the biopsy instruments are specially constructed 
with a biopsy head and a handle shank [5, 15].
Performing the biopsy under colposcopic guidance allows the colposcopist to avoid mis-
guided therapeutic decisions.
Tischler forceps may be used to obtain a larger punch biopsy with an adequate depth. Other 
types include Kevorkian, Burke, or Eppendorfer biopsy forceps [1, 3].
To achieve the acetowhite reaction of the epithelium, the application of dilute 2–5% acetic acid 
is required.
Lugol’s solution would indicate that glycogen is present in the cells. When glycogen is absent, 
a keratinized area is present.
Monsel’s solution may be used to stop the bleeding after the biopsies are obtained.
Recent reports have suggested that the main purpose of colposcopy is to assess the entire 
squamo-columnar junction between the columnar epithelium and the squamous epithelium 
of the cervix. The transformation zone was located on the exocervix in most cases of younger 
women and the endocervix as the age increased. This is the most common place on the cervix 
for abnormal cells developing [1, 18, 31].
There was significant correlation between the increasing number of live births and dysplastic 
lesions. This is because the transformation zone is directly exposed to external agents and the 
cells are more susceptible to infection. Pre-cancer changes may occur many years after first 
HPV exposure [2, 10, 20, 22].
High-risk HPV types include 16, 18, 31, 33, 34, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68, and 70 types.
Low-risk HPV types include 6, 11, 42, 43, and 44 types.
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The primary immune response to HPV is cell-mediated; therefore, immune suppression 
induced by transplantation or immunodeficiency disease may contribute to the persistence of 
HPV and the development of cervical cancer [1, 3, 5, 30].
Recent studies using quantitative type-specific polymerase chain reaction (PCR) indicate that 
human herpesvirus 6 (HHV 6), human herpesvirus 7 (HHV 7), and cytomegalovirus (CMV) 
are not cofactors in the development of cervical carcinoma. It is well known that the HPV 
replication begins with the entry of the virus into the basal layer and progresses to the surface 
of the epithelium. HPV in association with other factors promoting cell transformation may 
lead to a gradual progression to malignancy [1, 5, 15, 26, 28, 32].
Some researchers have suggested that CIN II and CIN III are the only true cervical cancer 
precursor.
In women with ASC-US, if HPV-DNA testing is negative for high-risk HPV types, cytology 
testing at 12 month is recommended [11, 12, 16].
AGUS is usually managed with colposcopy or cone biopsy.
In patients with low-grade squamous intraepithelial lesions (LGSIL), Pap test should be per-
formed at 6 and 12 months. Furthermore, they should be directly referred back to colposcopy 
if cytology is unsatisfactory (ASC-US or greater). Also, if colposcopy is unsatisfactory, a Pap 
smear should be performed at 6 and 12 months with referral back to colposcopic examination 
[20, 22, 32–34].
6. Treatment after diagnosis of cancer
Microinvasive cancers are treated by excisional cone biopsy. Early invasive cervical cancers 
are treated with radical hysterectomy or radiotherapy. In addition, the patients can also ben-
efit from concurrent chemotherapy [1, 3, 5, 11, 16].
Locally advanced cancers are treated with radiotherapy. Patients with biopsy confirmed CIN 
undergo standard practice for CIN [3, 15, 16, 24].
Several immunomodulatory agents, which have spectrum activity against DNA viruses, have 
been used as treatment for cervical lesions. Cytotoxic agents that arrest mitosis in metaphase 
also have the ability to treat genital warts [3, 14, 15, 24, 30].
7. Conclusion
The incidence of cervical cancer has declined in the last years due to screening programs that 
use Pap smear testing. The procedure of colposcopy is used in the criteria for the management 
of cervical cancer and as a part of continuous professional self-development.
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Methods such as colposcopic examination and HPV-DNA testing have the ability to detect 
precursor lesions. Also, the improvements in colposcopy greatly facilitate the intervention on 
women at risk for cervical cancer. Cervical cancer risk remains high; thus, the potential benefit 
of colposcopy examination should be balanced against the risk. However, these techniques 
might have been expected to contribute toward managing women with abnormal cytology [1, 
2, 5, 24, 30, 31, 35, 36].
In conclusion, the purpose of colposcopy is to assist the physician in clarifying abnormal find-
ings and to exclude the presence of invasive cancer.
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